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Unstable angina pectorisAbstract Background: Acute coronary syndrome remains the principal cause of death, so the
early diagnosis is of great importance. Cardiac troponin is the preferred biomarker for acute myo-
cardial infarction. Cardiac chest pain immediately increased copeptin secretion. The combination of
copeptin and cardiac troponin I is being suggested for early diagnosis of acute coronary syndrome.
Subject: It was done to emphasize the importance of association of copeptin, cardiac troponin I
and high sensitive C reactive protein to conﬁrm the diagnosis of acute myocardial infarction or
unstable angina pectoris in patients with a cardiac chest pain.
Method: The current study enrolled 22 patients with acute myocardial infarction as group i and
33 patients with unstable angina pectoris as group ii. The third group consisted of 23 apparently
healthy persons. Patients and controls were subjecting to laboratory investigations, which include
the levels of copeptin, high-sensitivity cardiac troponin high sensitive C reactive protein creatine
kinase MB fraction, lipid and I proﬁle.
Results: We found a signiﬁcant increase of copeptin in group i when compared to group iii
(30.01 ± 12.92) (9.54 ± 3.55), respectively, p value = 0.000 and group ii (30.01 ± 12.92)
(11.16 ± 4.58) respectively, p value 0.000, but a non-signiﬁcant difference in group ii when com-
pared to group iii (11.16 ± 4.58) (9.54 ± 3.55) respectively, p value = 0.160. Also cardiac troponin
242 Z.H. El Sayed et al.I showed a signiﬁcant increase in group i when compared to group ii (136.73 ± 26.07)
(11.18 ± 3.79), p value = 0.000, and group iii (136.73 ± 26.07) (9.61 ± 3.70) respectively, p
value = 0.000, but a non-signiﬁcant difference between group ii (11.18 ± 3.79), and group iii
(9.61 ± 3.70), p value = 0.129. There was a positive correlation between copeptin and cardiac tro-
ponin I within group i, r= 0.718, p value = 0.000.
Conclusion: In suspected acute coronary syndrome, determination of copeptin and cardiac tro-
ponin I provides a remarkable negative predictive value, which aids in early and safe ruling out of
myocardial infarction.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Acute coronary syndrome (ACS) remains the principal cause
of death around the world in 2011 [1]. Diagnosis and accurate
exclusion are of great importance in the emergency department
to ensure early effective treatment. Cardiac troponins (cTn) are
the preferred biomarkers for detection of myocardial cell
necrosis and they are essential for the diagnosis of acute myo-
cardial infarction (AMI) [2]. However, there remains a tropo-
nin-blind interval after onset of chest pain due to the delayed
release of cTn following a cardiac injury [3], and requires re-
peat measurement of cTn to discriminate between AMI and
unstable angina pectoris (UAP) [4]. Therefore, there is a need
for a biomarker that is released immediately in the event of
AMI [3]. The hope is that this new biomarker will enable early
decision making in clinical practice. AMI activates the main
hypothalamic stress hormone, arginine vasopressin (AVP)
[2]. Hence, AVP becomes an important marker; however,
due to its unstable nature and rapid clearance from plasma,
measurements of AVP are rarely reproducible [5]. Copeptin
is stored in the neurohypophyseal vesicles together with AVP
until they are secreted [2]. Copeptin is stable and easier to mea-
sure. Therefore, its level represents the production of AVP.
Thus, copeptin is a mirror of AVP concentration with high
prognostic accuracy [6]. Therefore, in patients with ACS, the
new biomarker copeptin as a marker of acute endogenous
stress [7] is expected to be elevated very early after AMI [8].
Therefore, the combination of a marker of endogenous stress
and a marker of cell necrosis has been suggested to improve
the diagnostic performance in chest pain patients at presenta-
tion in the emergency department [9].
1.1. Aim of work
This study was done to emphasize the importance of associa-
tion of copeptin, cardiac troponin i, high sensitive C reactive
protein and creatine kinase MB fraction, to conﬁrm the diag-
nosis of acute myocardial infarction or unstable angina pecto-
ris in patients with a cardiac chest pain.
2. Patients and methods
2.1. Patients and controls
AMI was the ﬁnal diagnosis in 22 patients (14 males and 8 fe-
males), their ages ranged between 46 and 73 years, and 33 pa-
tients with UAP (24 males and 9 females), and their ages
ranged between 47 and 71 years. They presented to the emer-
gency department of the National Heart Institute, Imbibe,Giza, Egypt, complaining of typical cardiac chest pain between
January 2013 and June 2013. Patients with hepatic or renal dis-
ease were excluded. Other 23 apparently healthy persons of
matching age served as the healthy control group of this study
for baseline normal value assessment. All investigations and
diagnosis of AMI and UAP were performed in accordance with
a standardized protocol in the National Heart Institute, Health
and Human Ethics Clearance Committee guidelines for Clinical
Researches. Local ethics committee approved the study proto-
col and informed consents were obtained from all subjects.
Patients and controls were divided into the following
groups (According to the current guidelines) [10]:
1- AMI patients as group i: consisted of 22 patients with a
mean age/years and SD of 59.59 ± 6.75.
2- USP as group ii: consisted of 33 patients with a mean of
age/years and SD of 58.82 ± 6.20.
3- Healthy control as group iii: consisted of 23 age
matched, with mean age/years and SD of 56.04 ± 6.27.
Comprehensive adult health history was taken and compre-
hensive physical examination was done for all studied
participants.
All studied participants were subjected to the following:
1- Standard 12-lead electrocardiography (ECG).
2- Trans-thoracic echocardiography.
3- Chest radiography (postero-anterior and lateral).
4- Laboratory investigations:-
a) Serum random blood glucose level.
b) Serum lipid proﬁle (total cholesterol, serum low-
density lipoprotein – cholesterol (LDL-c) and
triglycerides).
c) Liver function tests (total serum bilirubin, total
serum protein, prothrombin time, and international
normalized ratio).
d) Renal function tests (serum creatinine, serum blood
urea).
e) Total serum creatine kinase (CK).
f) Serum creatine kinase-MB fraction (CK-MB) .
g) Serum highly sensitive cardiac troponin i (hs-cTn I).
h) Serum copeptin.
i) Serum highly sensitive C reactive protein (hs-CRP).2.2. Sampling collection
- Five ml of venous blood was withdrawn, under aseptic con-
dition, from each patient and control. Then it was divided
as follows:
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serum creatine kinase (CK), serum creatine kinase-MB
fraction (CK-MB), alanine aminotransferase (ALT), highly
sensitive cardiac troponin I (hs-cTn I), Glucose, Urea and
highly sensitive C reactive protein (hs-CRP).
- 2 ml without anticoagulant (serum) to measure concentra-
tion of copeptin. The samples were lifted for 2 h at room
temperature before centrifugation for 20 min at approxi-
mately 1000g and stored at 20 C.
2.3. Quantitative determination of human copeptin (CPP)
by ELISA
The kits were supplied by Uscn Catalog NO E90365Hu.
2.3.1. Principle of this procedure
The microtiter plate provided in this kit had been pre-coated
with a monoclonal antibody speciﬁc to copeptin.
Standards or samples were then added to the appropriate
microtiter plate wells with a biotin-conjugated polyclonal anti-
body preparation speciﬁc for copeptin. Next, Avidin conju-
gated to Horseradish Peroxidase (HRP) was added to each
microplate well and incubated. After TMB substrate solution
was added, only those wells that contain copeptin, biotin-con-
jugated antibody and enzyme-conjugated Avidin will exhibit a
change in color. The enzyme–substrate reaction was termi-
nated by the addition of sulfuric acid solution and the color
change was measured spectrophotometrically at a wave length
of 450 nm ± 10 nm. The concentration of CPP in the samples
was then determined by comparing the O.D. of the samples to
the standard curve .The detection range is 15.6–1000 pg/ml.
This assay has high sensitivity and excellent speciﬁcity for
detection of copeptin.2.4. Determination of concentration of C- reactive protein
by ELISA
The kit supplied by GenWay Catalog NO 40-052-115042.
2.4.1. Principle of this procedure
The hsCRP ELISA was based on the principle of a solid phase
enzyme-linked immunosorbent assay.
The assay system utilizes a unique monoclonal antibody di-
rected against a distinct antigenic determinant on the CRP
molecule. This mouse monoclonal anti-CRP antibody was
used for solid phase immobilization (on the microtiter wells).
A goat anti-CRP antibody is in the antibody-enzyme (horse-
radish peroxidase) conjugate solution. The test sample was al-
lowed to react simultaneously with the two antibodies,
resulting in the CRP molecules being sandwiched between
the solid phase and enzyme-linked antibodies. After a 45-
min incubation at room temperature, the wells were washed
with water to remove unbound labeled antibodies. A tetra-
methylbenzidine (TMB) reagent was added and incubated
for 20 min, resulting in the development of blue color. The col-
or development was stopped with the addition of 1 N HCl
changing the color to yellow. The concentration of CRP was
directly proportional to the color intensity of the test sample.
Absorbance was measured spectrophotometrically at 450 nm.2.5. Statistical analysis
All information was recorded in a database created with
Microsoft Ofﬁce Access 2007. Calculations were done by
means of statistical software packages namely SPSS (Statistical
Package for the Social Sciences), version 17.
Data were tabulated and statistically analyzed to evaluate
the difference between the whole groups under investigations
as regards the various parameters. Together, correlation was
tried in between the essential studied parameters. The statis-
tical analysis included the arithmetic mean value, standard
deviation, and hypothesis student’s t test. Pearson’s test was
used to study the correlation ‘‘r’’ and the signiﬁcance of
result (p).
3. Results
3.1. Baseline characteristics of all groups
Table 1 provides the baseline characteristics of the overall
study population. Discharge diagnosis of AMI was made in
22 patients, having an ST segment elevation, pathological Q
and T wave inversion. Furthermore, they had highest levels
of copeptin, hs-cTn I, hs-CRP, LDL-C, and CK-MB. The
diagnosis of UAP was made in 33 patients. Traditional risk
factors were present in AMI and UAP patients. All UAP pa-
tients and controls had normal ECG.
3.2. Comparison between AMI patients and controls
When comparing between group i and group iii patients, we
found a highly signiﬁcant increase of all serum CK-MB, serum
LDL-c, serumrandomblood glucose level, hs-CRP, hs-troponin
I and serum copeptin. There were non-signiﬁcant differences
when comparing between group i and iii as regards the mean
of all; age, height and BMI, as shown in Table 2 and Fig. 1.
3.3. Comparison between UAP patients and controls
Table 3 showed that, there were non-signiﬁcant differences as
regards the age, height, weight, BMI, CK-MB, hs-cTn i and
copeptin, when compared between group ii and group iii pa-
tients. The comparison of both random blood glucose and
hs-CRP in previous groups, was signiﬁcantly increased in ran-
dom blood glucose, and highly signiﬁcant in hs-CRP, as shown
in Fig. 1.
3.4. Comparison between UAP and AMI patients
Table 4 showed that, there were highly signiﬁcant increases
between group ii and group i patients as regards CK-MB,
LDL-c, random blood glucose level, hs-CRP, hs-Tcn I and
copeptin while a non-statistically signiﬁcant difference was
found between the two groups as regards age, height, weight
and BMI, as shown in Fig. 1.
3.5. Correlation between copeptin in AMI patients
Table 5 shows the correlation coefﬁcient of copeptin and other
parameters within AMI patient group. We found that, there
Table 1 Baseline characteristics and presentation in the overall population according to ﬁnal diagnosis.
Parameters Group i (mean ± SD) Group ii (mean ± SD) Group iii (mean ± SD)
Age/years (59.59 ± 6.75) (58.82 ± 6.2) (56.04 ± 6.27)
Sex (men/women) (n)/% (14/8)–(70/30%) (22/9)–(71/29%) (16/7)–(70/30%)
Height (m) 1.70 ± 0.07 1.71 ± 0.08 1.71 ± 0.08
Weight (kg) 90.00 ± 13.54 88.24 ± 11.16 84.65 ± 8.38
Body mass index (m2/k) 31.04 ± 5.03 30.13 ± 4.41 29.38 ± 3.24
Hypertension 18 30 No
Hypercholesterolaemia 22 33 No
Diabetes mellitus 15 23 No
Family history 22 32 No
Smoking 14 22 No
Aspirin 22 33 No
Beta-adrenergic blocker 22 33 No
ACE inhibitora or ARBb 22 30 No
Statin 22 33 No
Clopidogrel 10 No No
Duration of chest pain (h) 6–8/h 8–10/h No chest pain
Electrocardiogram:
Pathological Q wave All 22 patients had these changes All patients have normal ECG All patients have normal ECG
ST-segment elevation
T-wave changes
LDL(U/L)c 394.55 ± 101.71 323.67 ± 84.07 227.00 ± 44.50
CK-MB(U/L)d 45.59 ± 12.04 7.76 ± 3.43 6.22 ± 1.90
Random blood glucose (mg/dL) 149.09 ± 79.90 93.15 ± 10.93 87.39 ± 8.66
hs-cTnI (pg/ml)e 136.73 ± 26.07 11.18 ± 3.79 9.61 ± 3.70
Copeptin (pmol/L) 30.01 ± 12.92 11.16 ± 4.58 9.54 ± 3.55
CRP (mg/L)f 25.66 ± 13.41 15.24 ± 6.99 4.89 ± 3.59
a Angiotensin-converting enzyme.
b Angiotensin II receptor blocker.
c Low density lipoprotein.
d Creatine kinase-MB.
e High-sensitivity cardiac troponin.
f C reactive protein , means ± standard deviations or numbers of observations in the corresponding group.
Table 2 Comparison between group (i) and group (iii).
Parameters Group i Group iii Independent t-test Signiﬁcant
Mean SD Mean SD t p-value
Height/m 1.70 0.07 1.71 0.08 0.245 0.808 NS
Weight/kg 90.00 13.54 84.65 8.38 1.601 0.117 NS
BMI (m2/k)a 31.04 5.03 29.38 3.24 1.322 0.193 NS
CK-MB (U/L)b. 45.59 12.04 6.22 1.90 15.216 0.000 HS
LDL (U/L)c 394.55 101.71 227.00 44.50 7.214 0.000 HS
Random blood glucose (mg/dL) 149.09 79.90 87.39 8.66 3.683 0.001 HS
CRP (mg/L)d 25.66 13.41 4.89 3.59 7.168 0.000 HS
hs-cTnI (pg/ml)e 136.73 26.07 9.61 3.70 22.650 0.000 HS
Copeptin (pmol/L) 30.01 12.92 9.54 3.55 8.660 0.000 HS
a Body mass index.
b Creatine kinase-MB.
c Low density lipoprotein.
d C reactive protein.
e High-sensitivity cardiac troponin I.
244 Z.H. El Sayed et al.was a non-signiﬁcant difference but positive correlation be-
tween copeptin and CK-MB r= 0.201 and p= .370, and be-
tween copeptin and LDL-c, r= 0.298 and p= 0.196. But
there was a highly signiﬁcant positive correlation between
copeptin and both hs-cTn i and hs-CRP, (r= 0.718 and
p= 0.000), (r= 0.699 and p= 0.000) respectively, as shown
in Fig. 1.4. Discussion
ACS comprises life-threatening conditions that require imme-
diate and efﬁcient medical care to improve outcome. A previ-
ous study reported that nearly one third of patients with ACS
have normal levels of hs-cTn T and the majority of these pa-
Figure 1 Show the relations of cardiac biomarkers in all groups.
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superior biomarkers for AMI diagnosis [11]. The new bio-
marker copeptin was expected to be elevated very early after
an AMI [12].
In the current study, we observed that, the copeptin levels
were signiﬁcantly increased in AMI than in unstable angina
patients. While there was a non-signiﬁcant difference betweenTable 3 Comparison between group ii and group iii.
Parameters Group ii Gro
Mean SD Mea
Height/m 1.71 0.08 1.
Weight/kg 88.24 11.16 84.
BMI (m2/k) a 30.13 4.41 29.
CK-MB (U/L)b 7.76 3.43 6.
LDL (U/L) c 323.67 84.07 227.
Random blood glucose (mg/dL) 93.15 10.93 87.
CRP (mg/L) d 15.24 6.99 4.
hs-cTn I (pg/ml) e 11.18 3.79 9.
Copeptin (pmol/ L) 11.16 4.58 9.
a Body mass index.
b Creatine kinase-MB.
c Low density lipoprotein.
d C reactive protein.
e High-sensitivity cardiac troponin I.
Table 4 Comparison between group (ii) and group (i).
Parameters Group ii Grou
Mean SD Mea
Height/m 1.71 0.08 1.7
Weight/kg 88.24 11.16 90.0
BMI (m2/k) a 30.13 4.41 31.0
Serum CK-B (U/L) b 7.76 3.43 45.5
LDL (U/L) c 323.67 84.07 394.5
Random blood glucose (mg/dL) 93.15 10.93 149.0
CRP (mg/L) d 15.24 6.99 25.6
hs-cTnI (pg/ml) e 11.18 3.79 136.7
Copeptin (pmol/L) 11.16 4.58 30.0
a Body mass index.
b Creatine kinase-MB.
c Low density lipoprotein.
d C reactive protein.
e High-sensitivity cardiac troponin I.UAP patients and healthy controls. This result suggested that,
AMI induces a higher level of copeptin secretion than UAP pa-
tients and control subjects. This ﬁnding was well in agreement
with Folli and his college study that showed the increase in
copeptin levels was strictly related to stress occurring immedi-
ately with the onset of AMI [13]. Karakas and his colleague
suggested that, copeptin may be of less value in diagnoses of
unstable angina patients [14]. This is because; the unstable an-
gina pectoris is not accompanied by necrosis and does not
cause sufﬁcient endogenous stress for copeptin release [9].
Kaplan–Meier analysis showed that copeptin levels above
the diagnostic cut-off (<14 pmol/L) were associated with ele-
vated intermediate-term (180 days) mortality, while no patient
with copeptin values below the cut-off died [15] Therefore the
use of copeptin was proposed in AMI patients who present
soon after symptom onset (0–4 h) while troponin is still nega-
tive [16].
Another study reported that, copeptin provided a little clin-
ical information when measured alone [17], because the exact
trigger cause for copeptin release in AMI was unknown; it
was generally considered a marker of acute life-threateningup iii Independent t-test Signiﬁcant
n SD t p-Value
71 0.08 0.753 0.454 NS
65 8.38 1.306 0.197 NS
38 3.24 0.691 0.493 NS
22 1.90 1.540 0.056 NS
00 44.50 5.036 0.000 HS
39 8.66 2.106 0.040 S
89 3.59 6.518 0.000 HS
61 3.70 1.543 0.129 NS
54 3.55 1.423 0.160 NS
p i Independent t-test Signiﬁcant
n SD t p-Value
0 0.07 0.490 0.626 NS
0 13.54 0.525 0.602 NS
4 5.03 0.711 0.480 NS
9 12.04 17.108 0.000 HS
5 101.71 2.815 0.007 HS
9 79.90 3.985 0.000 HS
6 13.41 3.772 0.000 HS
3 26.07 27.359 0.000 HS
1 12.92 7.712 0.000 HS
Table 5 Correlation between CPP and the other studied
parameters within group (i).
Parameters Copeptin
Group i
r p-Value Signiﬁcant
CK-MBa 0.201 0.370 NS
LDL(U/L) b 0.298 0.196 NS
hs-cTn i(pg/ml) c 0.718 0.000 HS
CRP (mg/L) d 0.699 0.000 HS
a Creatine kinase-MB.
b Low density lipoprotein.
c High-sensitivity cardiac troponin I.
d C reactive protein.
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prognostic marker reﬂecting disease severity in patients with
a wide array of diseases [5]. For this reason it should be as-
sessed along with other more speciﬁc biomarkers, such as car-
diac troponins.
In the current study, there were highly signiﬁcant increases
of both copeptin and hs-cTnI levels in AMI patients when
compared to unstable angina patients. Nursalim and his col-
league described a negative predictive value of up to 99.7%
using the combination of low level of copeptin and low level
of hs-cTnT for ruling out AMI [18]. The combination of hs-
cTnT and copeptin decreased the number of false negative as
compared to hs-cTnT alone [9]. The results of our study are
in accordance with the known fact that copeptin is an endog-
enous stress hormone reaching markedly elevated levels in crit-
ically ill patients [12]. However, in the ﬁnal exclusion of AMI,
copeptin is not able to replace cTnT [19], but adding copeptin
to cTnI allowed safe rule out of AMI with a negative predictive
value >99% in patients presenting with suspected acute coro-
nary syndromes [8]. The recent presentation of the Biomarkers
In Cardiology-8 (BIC-8) was the ﬁrst interventional clinical
trial to study whether it is safe to discharge suspected ACS pa-
tients who test troponin and copeptin negative at admission on
emergency department [20]. The limitation of our study is that,
the present measurements of copeptin and hscTnI concentra-
tions were performed after a time interval elapsed since onset
of chest pain and presentation to the emergency department
and this might be responsible for the lack of an association
between copeptin and ACS.
In our study, we found that, hs-CRP level was highly signif-
icantly increased in AMI patients than in those with UAP pa-
tients. Accordingly, it seems that hs-CRP could be helpful in
differentiating AMI patients from UAP patients. As we found,
there was a highly signiﬁcant increase in patients with UAP
than in healthy controls. Accordingly, hs-CRP could be assess-
ing its diagnostic value in ACS. Madadi and his colleague
found that, patients with AMI had higher levels of hs-CRP
in comparison with unstable angina [21]. Yip and his colleague
reported hs-CRP levels of 2.95 mg/L in patients with AMI and
1.35 mg/L in subjects with UAP [22]. But Madadi and his col-
league showed that, hs-CRP levels were equal to or higher than
3.27 mg/L more likely to be associated with AMI, so the cut-
off point for differentiating between the two diseases was cal-
culated as 3.27 mg/L. [21]. Another study, found that hs-CRP
level is a predictor of mortality over the next ﬁve years in
patients with ACS [21]. This is because the inﬂammation isone of the pathophysiological mechanisms of most acute car-
diovascular conditions including ACS [19] [23], and the bene-
ﬁts of elevated hs-CRP post ACS are indicating the level of
myocardial inﬂammation [24]. Also, this biomarker was asso-
ciated with atherosclerotic plaque rupture, which is probably a
reason for AMI. Patients with unstable angina who had higher
levels of hs-CRP had been suggested to be at greater risk of
mortality and AMI [25].
In our study, there was a highly positive correlation between
copeptin and hs-cTnI (r= 0.718, p= 0.000) within AMI pa-
tients. Karakas and his colleague found amodest positive corre-
lation between copeptin andhs-cTnT inAMIpatients [14].Also,
in a study by Lotze and his colleague, they reported a positive
correlation between hs-cTnT and copeptin at the time of initial
AMI presentation (r= 0.41; p< 0.001) [3].
5. Conclusion
In suspected ACS patients, determination of copeptin and hs-
troponin i provides a remarkable negative predictive value
which aids in early and safe ruling-out of myocardial
infarction.
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